Drug-induced Tumor-specific Cytotoxicity In a Whole Tissue model of Human Pancreatic Ductal Adenocarcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Sep 5

PMID 36059619

Authors

Carlos Fernandez Moro

Arun Kumar Selvam

Mehran Ghaderi

Ville N Pimenoff

Marco Gerling

Bela Bozoky

Soledad Pouso Elduayen

Joakim Dillner

Mikael Bjornstedt

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. PDAC has a dismal prognosis and an inherent resistance to cytostatic drugs. The lack of reliable experimental models is a severe limitation for drug development targeting PDAC. We have employed a whole tissue culture model to explore the effect of redox-modulation by sodium selenite on the viability and growth of PDAC. Drug-resistant tumors are more vulnerable to redox-active selenium compounds because of high metabolic activity and redox imbalance. Sodium selenite efficiently and specifically reduced PDAC cell viability (p <0.02) (n=8) and decreased viable tumor cell outgrowth (p<0.05) while preserving non-neoplastic tissues. Major cellular responses (damaged tumor cells > 90%, tumor regression grades III-IV according to Evans) were observed for sodium selenite concentrations between 15-30 µM. Moreover, selenium levels used in this study were significantly below the previously reported maximum tolerated dose for humans. Transcriptome data analysis revealed decreased expression of genes known to drive PDAC growth and metastatic potential (CEMIP, DDR2, PLOD2, P4HA1) while the cell death-inducing genes (ATF3, ACHE) were significantly upregulated (p<0.0001). In conclusion, we report that sodium selenite has an extraordinary efficacy and specificity against drug-resistant pancreatic cancer in an organotypic slice culture model. Our organotypic tissue slice culture model can be used to test a variety of drug candidates for swift and reliable drug responses to individual PDAC cases.

Citing Articles

Sodium Selenite Induces Autophagy and Apoptosis in Cervical Cancer Cells via Mitochondrial ROS-Activated AMPK/mTOR/FOXO3a Pathway.

Lv C, Zeng Q, Qi L, Wang Y, Li J, Sun H Antioxidants (Basel). 2024; 13(8).

PMID: 39199249 PMC: 11352036. DOI: 10.3390/antiox13081004.

Trace elements in pancreatic cancer.

Yanjun Y, Jing Z, Yifei S, Gangzhao G, Chenxin Y, Qiang W Cancer Med. 2024; 13(14):e7454.

PMID: 39015024 PMC: 11252496. DOI: 10.1002/cam4.7454.

Research on the biological mechanism and potential application of CEMIP.

Liu Y, Hu G, Li Y, Kong X, Yang K, Li Z Front Immunol. 2023; 14:1222425.

PMID: 37662915 PMC: 10471826. DOI: 10.3389/fimmu.2023.1222425.

Intravenous Infusion of High Dose Selenite in End-Stage Cancer Patients: Analysis of Systemic Exposure to Selenite and Seleno-Metabolites.

Breuer O, Brodin O, Razaghi A, Brodin D, Gammelgaard B, Bjornstedt M Biomedicines. 2023; 11(2).

PMID: 36830832 PMC: 9953619. DOI: 10.3390/biomedicines11020295.

Selenium-Containing Agents Acting on Cancer-A New Hope?.

Garbo S, Di Giacomo S, Lazewska D, Honkisz-Orzechowska E, Di Sotto A, Fioravanti R Pharmaceutics. 2023; 15(1).

PMID: 36678733 PMC: 9860877. DOI: 10.3390/pharmaceutics15010104.

References

Jorgenson T, Zhong W, Oberley T . Redox imbalance and biochemical changes in cancer. Cancer Res. 2013; 73(20):6118-23. PMC: 3800221. DOI: 10.1158/0008-5472.CAN-13-1117. View

Clark L, Combs Jr G, Turnbull B, Slate E, Chalker D, Chow J . Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996; 276(24):1957-63. View

Evans D, Rich T, Byrd D, Cleary K, Connelly J, Levin B . Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992; 127(11):1335-9. DOI: 10.1001/archsurg.1992.01420110083017. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Afgan E, Baker D, Batut B, van den Beek M, Bouvier D, cech M . The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. Nucleic Acids Res. 2018; 46(W1):W537-W544. PMC: 6030816. DOI: 10.1093/nar/gky379. View

Neoptolemos J, Palmer D, Ghaneh P, Psarelli E, Valle J, Halloran C . Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017; 389(10073):1011-1024. DOI: 10.1016/S0140-6736(16)32409-6. View

Kleeff J, Korc M, Apte M, La Vecchia C, Johnson C, Biankin A . Pancreatic cancer. Nat Rev Dis Primers. 2016; 2:16022. DOI: 10.1038/nrdp.2016.22. View

Bandura L, Drukala J, Wolnicka-Glubisz A, Bjornstedt M, Korohoda W . Differential effects of selenite and selenate on human melanocytes, keratinocytes, and melanoma cells. Biochem Cell Biol. 2005; 83(2):196-211. DOI: 10.1139/o04-130. View

Jassal B, Matthews L, Viteri G, Gong C, Lorente P, Fabregat A . The reactome pathway knowledgebase. Nucleic Acids Res. 2019; 48(D1):D498-D503. PMC: 7145712. DOI: 10.1093/nar/gkz1031. View

10.

Bjorkhem-Bergman L, Jonsson K, Eriksson L, Olsson J, Lehmann S, Paul C . Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase. Biochem Pharmacol. 2002; 63(10):1875-84. DOI: 10.1016/s0006-2952(02)00981-4. View

11.

Janssen Q, Buettner S, Suker M, Beumer B, Addeo P, Bachellier P . Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. J Natl Cancer Inst. 2019; 111(8):782-794. PMC: 6695305. DOI: 10.1093/jnci/djz073. View

12.

Tarze A, Dauplais M, Grigoras I, Lazard M, Ha-Duong N, Barbier F . Extracellular production of hydrogen selenide accounts for thiol-assisted toxicity of selenite against Saccharomyces cerevisiae. J Biol Chem. 2007; 282(12):8759-67. DOI: 10.1074/jbc.M610078200. View

13.

Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

14.

Verbeke C, Knapp J, Gladhaug I . Tumour growth is more dispersed in pancreatic head cancers than in rectal cancer: implications for resection margin assessment. Histopathology. 2011; 59(6):1111-21. DOI: 10.1111/j.1365-2559.2011.04056.x. View

15.

Szyller J, Bil-Lula I . Heat Shock Proteins in Oxidative Stress and Ischemia/Reperfusion Injury and Benefits from Physical Exercises: A Review to the Current Knowledge. Oxid Med Cell Longev. 2021; 2021:6678457. PMC: 7868165. DOI: 10.1155/2021/6678457. View

16.

Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M . Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun. 2015; 6:6169. PMC: 4351621. DOI: 10.1038/ncomms7169. View

17.

Jiang X, Seo Y, Chang J, Coveler A, Nigjeh E, Pan S . Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment. Oncoimmunology. 2017; 6(7):e1333210. PMC: 5543820. DOI: 10.1080/2162402X.2017.1333210. View

18.

Encarnacion-Rosado J, Kimmelman A . Harnessing metabolic dependencies in pancreatic cancers. Nat Rev Gastroenterol Hepatol. 2021; 18(7):482-492. PMC: 8249349. DOI: 10.1038/s41575-021-00431-7. View

19.

Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D . Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A. 2010; 107(18):8352-6. PMC: 2889536. DOI: 10.1073/pnas.0907676107. View

20.

Olm E, Fernandes A, Hebert C, Rundlof A, Larsen E, Danielsson O . Extracellular thiol-assisted selenium uptake dependent on the x(c)- cystine transporter explains the cancer-specific cytotoxicity of selenite. Proc Natl Acad Sci U S A. 2009; 106(27):11400-5. PMC: 2708693. DOI: 10.1073/pnas.0902204106. View